NASDAQ:INCY

Incyte Stock Forecast, Price & News

$82.66
+0.02 (+0.02 %)
(As of 06/15/2021 10:51 AM ET)
Add
Compare
Today's Range
$82.27
$82.88
50-Day Range
$79.87
$87.53
52-Week Range
$75.52
$110.36
Volume13,446 shs
Average Volume1.00 million shs
Market Capitalization$18.18 billion
P/E Ratio38.09
Dividend YieldN/A
Beta0.81
30 days | 90 days | 365 days | Advanced Chart
Receive INCY News and Ratings via Email

Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter.


Incyte logo

About Incyte

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Headlines

Incyte (NASDAQ:INCY) Given "Outperform" Rating at William Blair
Incyte (NASDAQ:INCY) Given "Outperform" Rating at William Blair
June 15, 2021 |  americanbankingnews.com
Incyte (NASDAQ:INCY) Receives "Sell" Rating from SVB Leerink
Incyte (NASDAQ:INCY) Receives "Sell" Rating from SVB Leerink
June 15, 2021 |  americanbankingnews.com
Incyte (NASDAQ:INCY) Shares Gap Down to $87.53
Incyte (NASDAQ:INCY) Shares Gap Down to $87.53
June 11, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

1.87 out of 5 stars

Medical Sector

142nd out of 2,100 stocks

Commercial Physical Research Industry

1st out of 37 stocks

Analyst Opinion: 2.2Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Incyte (NASDAQ:INCY) Frequently Asked Questions

Is Incyte a buy right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Incyte stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares.
View analyst ratings for Incyte
or view top-rated stocks.

What stocks does MarketBeat like better than Incyte?

Wall Street analysts have given Incyte a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Incyte wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Incyte's next earnings date?

Incyte is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Incyte
.

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) posted its quarterly earnings data on Tuesday, May, 4th. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.42 by $0.25. The biopharmaceutical company had revenue of $604.72 million for the quarter, compared to analyst estimates of $657.73 million. Incyte had a net margin of 17.70% and a trailing twelve-month return on equity of 20.10%. The company's revenue was up 6.4% compared to the same quarter last year. During the same period last year, the firm posted ($2.86) EPS.
View Incyte's earnings history
.

How has Incyte's stock price been impacted by Coronavirus (COVID-19)?

Incyte's stock was trading at $71.90 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, INCY stock has increased by 15.0% and is now trading at $82.66.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for INCY?

14 brokerages have issued 12 month target prices for Incyte's stock. Their forecasts range from $70.00 to $121.00. On average, they expect Incyte's share price to reach $97.00 in the next twelve months. This suggests a possible upside of 17.3% from the stock's current price.
View analysts' price targets for Incyte
or view top-rated stocks among Wall Street analysts.

Who are Incyte's key executives?

Incyte's management team includes the following people:
  • Mr. Herve Hoppenot, Chairman, Pres & CEO (Age 61, Pay $2.55M)
  • Ms. Christiana Stamoulis, Exec. VP & CFO (Age 50, Pay $989.39k)
  • Dr. Vijay K. Iyengar M.D., Exec. VP of Global Strategy & Corp. Devel. (Age 48, Pay $945.9k)
  • Dr. Barry P. Flannelly M.B.A., Pharm.D., MBA, Exec. VP & GM of North America (Age 63, Pay $833.63k)
  • Dr. Steven H. Stein, Exec. VP & Chief Medical Officer (Age 54, Pay $967.8k)
  • Mr. Michael James Morrissey, Exec. VP & Head of Global Technical Operations (Age 57)
  • Dr. Dashyant Dhanak Ph.D., Exec. VP & Chief Scientific Officer (Age 60)
  • Ms. Christine Chiou, Head of Investor Relations
  • Ms. Maria E. Pasquale, Exec. VP & Gen. Counsel (Age 55)
  • Ms. Pamela M. Murphy, VP of Investor Relations & Corp. Communications (Age 70)

What is Hervé Hoppenot's approval rating as Incyte's CEO?

22 employees have rated Incyte CEO Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among Incyte's employees.

Who are some of Incyte's key competitors?

What other stocks do shareholders of Incyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

What is Incyte's stock symbol?

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Who are Incyte's major shareholders?

Incyte's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Baker BROS. Advisors LP (14.55%), Price T Rowe Associates Inc. MD (13.67%), BlackRock Inc. (8.04%), Capital International Investors (2.50%), Renaissance Technologies LLC (2.23%) and Geode Capital Management LLC (1.54%). Company insiders that own Incyte stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jean Jacques Bienaime, Jonathan Elliott Dickinson, Maria E Pasquale, Michael James Morrissey, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends for Incyte
.

Which major investors are selling Incyte stock?

INCY stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Capital International Investors, Renaissance Technologies LLC, UBS Asset Management Americas Inc., Canada Pension Plan Investment Board, Nissay Asset Management Corp Japan ADV, State of Wisconsin Investment Board, and BlackRock Inc.. Company insiders that have sold Incyte company stock in the last year include Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Michael James Morrissey, Paul Trower, Steven H Stein, and Yao Wenqing.
View insider buying and selling activity for Incyte
or view top insider-selling stocks.

Which major investors are buying Incyte stock?

INCY stock was purchased by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Camber Capital Management LP, Armistice Capital LLC, Royal Bank of Canada, Virginia Retirement Systems ET AL, Geode Capital Management LLC, Polar Capital Holdings Plc, and D. E. Shaw & Co. Inc.. Company insiders that have bought Incyte stock in the last two years include Bros Advisors Lp Baker, and Herve Hoppenot.
View insider buying and selling activity for Incyte
or or view top insider-buying stocks.

How do I buy shares of Incyte?

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Incyte's stock price today?

One share of INCY stock can currently be purchased for approximately $82.66.

How much money does Incyte make?

Incyte has a market capitalization of $18.18 billion and generates $2.67 billion in revenue each year. The biopharmaceutical company earns $-295,700,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis.

How many employees does Incyte have?

Incyte employs 1,773 workers across the globe.

When was Incyte founded?

Incyte was founded in 1991.

What is Incyte's official website?

The official website for Incyte is www.incyte.com.

Where are Incyte's headquarters?

Incyte is headquartered at 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803.

How can I contact Incyte?

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]


This page was last updated on 6/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.